12471 results for
Refine Your Search
Jalpa Doshi
Jalpa Doshi, PhD, is a Professor at the University of Pennsylvania and Director of Value Based Insurance Design Initiatives at the Center for Health I…
Impact of Insurance Type and Cost Sharing on Equity in Access to Oral Anticancer Medications for Blood Cancers
This project will evaluate the association of insurance type with insurer rejection and patient abandonment of new OAM prescriptions for blood cancers…
Oreofe Odejide
Dr. Odejide is a health services researcher, a hematologic oncologist at the Cancer Institute, and an Assistant Professor of Medicine at Harvard Medi…
Health Insurance and End-of-Life Care for People with Hematologic Malignancies
Patients with blood cancers from racial and ethnic minority groups are more likely to experience suboptimal (EOL) care. These disparities may be part…
Together Teens & 20s by St. Jude
Produced by St. Jude Children’s Research Hospital, Together by St. Jude is an online resource providing information and education for adolescents and …
Together by St. Jude
Produced by St. Jude Children’s Research Hospital, Together by St. Jude is an online resource providing information and education for families facing …
Why: A Memoir of Love and Lymphoma
Why: A Memoir of Love and Lymphoma by John Melithoniotes NFB Publishing, , Pages, Paperback or Kindle ISBN: There is no test of a couple’s bond…
_dam_file_162296.jpg?crop=true&keep=c&w=400&h=400)
Honoring Blood Cancer Survivors
Throughout June, in commemoration of #NationalCancerSurvivorMonth, we at LLS have been highlighting the resilience and achievements of blood cancer su…
Designed biosensor to enhance CAR T cell therapy for multiple myeloma
We will develop a novel T cell therapy strategy for multiple myeloma (MM) that will combine existing chimeric antigen receptors (CARs) with a novel de…
Caroline Arber
Caroline Arber obtained her Doctor of Medicine from the University of Basel, Switzerland, and specialized in Internal Medicine and Hematology, with a …
Maximilian Stahl
Dr. Stahl is a member of the Adult Leukemia Group at Cancer Institute and an Instructor of Medicine at Harvard Medical School. His research focus is …
Memory-like natural killer cells and venetoclax to eradicate measurable residual disease in AML
This proposal is to conduct a phase I (early phase) clinical trial to test whether the combination of the approved targeted therapy venetoclax with N…
Ruben Carrasco
Dr. Carrasco earned his MD and PhD degrees at the University of Chile. Motivated by his desire to practice medicine at the highest level, he immigrate…
Developing selective inhibitors of the b-catenin/BCL9 transcriptional complex for myeloma therapy
The /BCL9 transcriptional complex, is a novel dependency in multiple myeloma (MM). Disruption of this complex inhibits MM cell growth in culture and i…
Jing Yang
My research focuses on the translation of bench works into new therapeutic approaches/strategies for multiple myeloma and other blood cancers. One of …
Qing Yi
I am a translational tumor immunologist. I have years of experience as a and published researcher and am one of the leading investigators in the fie…
Developing Novel CAR-T Cell Therapy For Hematologic Malignancies
We observed that patients with many hematologic cancers expressed high levels of DKK1 and generated novel human DKK1-A2 cells that can kill cancer ce…
Development of mutant GTPase-specific degraders for peripheral T cell lymphoma treatment
This project aims to develop targeted therapies against peripheral T cell lymphoma (PTCL), a diverse group of aggressive blood cancers with poor clini…
Yubin Zhou
Dr. Yubin Zhou is a professor of Translational Cancer Research at the Texas A&M University Institute of Biosciences and Technology. He is interested i…
Discovery and therapeutic targeting of novel mechanisms driving Double Hit Lymphomas
lymphoma (DHL) is an aggressive form of diffuse large lymphoma (DLBCL) defined by MYC and BCL2 rearrangements. DHL has been linked to very poor outc…
Stephen Gottschalk
I am a pediatric oncologist, who is interested in using the patient’s immune system to fight cancer. I grew up in Germany and moved to the US in afte…
CD70-directed CAR T-cell therapy for the treatment of relapsed/refractory pediatric AML
In this project, we will test an innovative therapy called CAR therapy for children with a type of cancer called AML. In the laboratory, we have iden…
Inhibition of PKCβ as a strategy for BTK inhibitor refractory CLL
Patients with CLL that have progressed on BTK inhibitors have high risk disease with few clinical options. Here we propose a novel, selective inhibito…
Shirong Li
I’m a Research Scientist at Columbia University Multiple Myeloma Program. I have over years of research experience, especially with profound expertis…
Mark Dawson
Professor Dawson is the Associate Director for Research Translation, a Program Head in Laboratory Research and a Consultant Haematologist at the Peter…